Maravai LifeSciences Holdings, Inc. (MRVI)

10,46 +0,60 (+6,09 %) À la clôture : 04:00PM EDT

Maravai LifeSciences Holdings, Inc.

10770 Wateridge Circle
Suite 200
San Diego, CA 92121
United States
858 546 0004
https://www.maravai.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 650

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Carl W. Hull	Co-Founder & Executive Chairman	617,67k	S.O.	1959
Mr. William E. Martin III	Chief Executive Officer	987,86k	S.O.	1975
Mr. Kevin M. Herde	Executive VP & CFO	548,62k	S.O.	1972
Dr. Peter Michael Leddy Ph.D.	Executive VP & Chief Administrative Officer	583,39k	S.O.	1963
Ms. Christine Dolan	Executive VP & GM of Cygnus Technologies	536,63k	S.O.	1968
Mr. Andrew Burch	President of Nucleic Acid Production	425,15k	S.O.	1969
Ms. Debra Hart	Senior Director of Investor Relations	S.O.	S.O.	S.O.
Mr. Kurt Oreshack	Executive VP, General Counsel & Secretary	701,4k	S.O.	1981
Ms. Rebecca Buzzeo	Executive VP & Chief Commercial Officer	S.O.	S.O.	S.O.
Dr. Kate E. Broderick Ph.D.	Chief Innovation Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Maravai LifeSciences Holdings, Inc. en date du 1 mai 2024 est 7. Les scores principaux sont Audit : 2; Société : 10; Droits des actionnaires : 7; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.